| Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian … PS Sever, B Dahlöf, NR Poulter, H Wedel, G Beevers, M Caulfield, ... The Lancet 361 (9364), 1149-1158, 2003 | 5526 | 2003 |
| Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the … B Dahlöf, PS Sever, NR Poulter, H Wedel, DG Beevers, M Caulfield, ... The Lancet 366 (9489), 895-906, 2005 | 4712 | 2005 |
| Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial S Yusuf, MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ... The Lancet 362 (9386), 777-781, 2003 | 3743 | 2003 |
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial JJV McMurray, J Östergren, K Swedberg, CB Granger, P Held, ... The Lancet 362 (9386), 767-771, 2003 | 2660 | 2003 |
| Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM … CB Granger, JJV McMurray, S Yusuf, P Held, EL Michelson, B Olofsson, ... The Lancet 362 (9386), 772-776, 2003 | 2574 | 2003 |
| Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme MA Pfeffer, K Swedberg, CB Granger, P Held, JJV McMurray, ... The Lancet 362 (9386), 759-766, 2003 | 2548 | 2003 |
| † Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text‡: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology … L Ryden, E Standl, M Bartnik, GV Berghe, J Betteridge, MJ De Boer, ... European heart journal supplements 9 (suppl_C), C3-C74, 2007 | 2206 | 2007 |
| Renal function as a predictor of outcome in a broad spectrum of patients with heart failure HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ... Circulation 113 (5), 671-678, 2006 | 1184 | 2006 |
| Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in … MR MacDonald, MC Petrie, F Varyani, J Östergren, EL Michelson, ... European heart journal 29 (11), 1377-1385, 2008 | 758 | 2008 |
| Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy P Svensson, U de Faire, P Sleight, S Yusuf, J Östergren Hypertension 38 (6), e28-e32, 2001 | 631 | 2001 |
| Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm … NR Poulter, H Wedel, B Dahlöf, PS Sever, DG Beevers, M Caulfield, ... The Lancet 366 (9489), 907-913, 2005 | 551 | 2005 |
| Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease J Östergren, P Sleight, G Dagenais, K Danisa, J Bosch, Y Qilong, S Yusuf European heart journal 25 (1), 17-24, 2004 | 440 | 2004 |
| Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): rationale and design K Swedberg, M Pfeffer, C Granger, P Held, J Mcmurray, G Ohlin, ... Journal of cardiac failure 5 (3), 276-282, 1999 | 408 | 1999 |
| Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy–CHARMES H Persson, E Lonn, M Edner, L Baruch, CC Lang, JJ Morton, J Östergren, ... Journal of the American College of Cardiology 49 (6), 687-694, 2007 | 347 | 2007 |
| Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in … E O’Meara, T Clayton, MB McEntegart, JJV McMurray, CC Lang, ... Circulation 113 (7), 986-994, 2006 | 334 | 2006 |
| Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of … E O’Meara, T Clayton, MB McEntegart, JJV McMurray, IL Piña, ... Circulation 115 (24), 3111-3120, 2007 | 307 | 2007 |
| Regression of left ventricular hypertrophy in human hypertension with irbesartan K Malmqvist, T Kahan, M Edner, C Held, A Hägg, L Lind, ... Journal of hypertension 19 (6), 1167-1176, 2001 | 276 | 2001 |
| Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved JK Rogers, SJ Pocock, JJV McMurray, CB Granger, EL Michelson, ... European journal of heart failure 16 (1), 33-40, 2014 | 252 | 2014 |
| Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial P Sever, B Dahlöf, N Poulter, H Wedel, G Beevers, M Caulfield, R Collins, ... European heart journal 27 (24), 2982-2988, 2006 | 220 | 2006 |
| Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme SJ Pocock, JJV McMurray, J Dobson, S Yusuf, CB Granger, EL Michelson, ... European heart journal 29 (21), 2641-2650, 2008 | 202 | 2008 |
